0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1532 Views 
0 Saved
0 Vote 1 Contributor1532 Views 0 SavedYou might also be interested in
Hello, please describe your problem in detail, then only we'll be able to provide you treatment costs. You can call us on +91-8010994994 and talk to our medical expert.
As any person with cancer knows, a cancer diagnosis also affects family members and friends. Sometimes, the complex feelings and lifestyle changes caused by cancer and its treatment become as overwhelming for others in your life as they are for you. Cancer has the greatest effect on marriages and....
While you can’t change some breast cancer risk factors – family history and aging, for example – there are others that you can control. Here are 5 ways to help protect your breast health: Watch your weight as being overweight or obese increases breast cancer risk. This is especially true after....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.